Bordeaux University, Bordeaux, France [email protected]
Dr. Girodet reports receiving speaker's fees and conference travel sponsorship from AstraZeneca, GlaxoSmithKline, Novartis Pharma, Pierre Fabre, Chiesi, Mundipharma, Takeda, and Boehringer Ingelheim; Dr. Raherison, receiving fees for participating in advisory boards with ALK, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, InterMune, Mundipharma, Novartis Pharma, and Teva Pharmaceuticals; and Dr. Molimard, receiving consulting fees from ALK, GlaxoSmithKline, Novartis Pharma, Pfizer, and Stallergen. No other potential conflict of interest relevant to this letter was reported.
